Business Wire

EXASOL

24.9.2020 10:17:10 CEST | Business Wire | Press release

Share
Exasol dominates its peer groups in BARC Data Management Survey 2020

Exasol , the high-performance analytics database, achieved 18 top-rankings and 4 leading positions in its two peer groups in The Data Management Survey 20. In addition, 100 percent of Exasol users chose the Exasol database because of its convincing performance and would recommend it to others. The survey was conducted by BARC (Business Application Research Center), Europe’s leading analyst firms for business software based in Würzburg, Germany.

“Exasol achieved truly remarkable results in the Data Management Survey 2020 with 18 top rankings,” said Timm Grosser, Senior Analyst Data & Analytics at BARC and author of the study. “Users gave Exasol the highest possible score for two crucial criteria when it comes to data platforms: 'performance' and 'platform reliability'. In today’s world, users need reliable and fast data for their operational and analytical processes. Similarly, the stability and performance of a data platform, even under pressure and high demand, are business-critical. Exasol has ranked impressively well in all the key areas and 100 percent of users surveyed in the Data Management Survey would recommend its high-performance analytics database to others.”

In the survey, twelve products were grouped into six peer groups to make them more comparable. The Exasol database was evaluated in both the Analytical Database Products peer group and the Data Warehouse Technologies peer group using twelve KPIs determined by BARC research. In both peer groups, the Exasol database was ranked top in the following categories:

  • Time to market;
  • Innovation power;
  • Performance;
  • Platform reliability;
  • Support quality;
  • Breadth of supported use cases;
  • Product satisfaction;
  • Recommendation.

In the group of Analytical Database Products, Exasol also achieved the top positions for Price-to-value and Functionality.

Exasol was ranked as a leader—among the top 25 to 30 percent of the products in the group—in the Developer Efficiency category in both peer groups, and in the data warehouse technologies peer group in the Price-to-value and Functionality categories.

“We are proud of our top rankings in BARC’s The Data Management Survey 2020. These excellent results show the high satisfaction of our customers,” said Aaron Auld, CEO of Exasol. “The fact that we scored ten out of ten in each of the two peer groups in the categories for Recommendation, Platform Reliability and Performance proves that we not only have the most powerful database for analytical workloads, but that we are committed to ensuring that our platform enables our customers to make data-driven decisions based on the most up-to-date data every day.”

The survey also shows that 93 percent of Exasol users use the database for data warehousing and business intelligence (BI) and 69 percent for data integration. Download the report, which includes a detailed overview of Exasol’s highlight results in BARC’S The Data Management Survey 2020.

###

About The Data Management Survey
The Data Management Survey 20 was conducted by BARC from December 2019 to March 2020. Altogether, 634 respondents worldwide answered a series of questions about their data management software. The survey offers a comparison of 12 leading data management tools across 12 criteria (KPIs) including developer efficiency, recommendation, time to market and product satisfaction. For more information, go to www.bi-survey.com.“

About Exasol
The Exasol high-performance analytics database is built to run faster than any other database, delivering next-level performance, scale and ease of use. Analyze billions of rows in seconds; run high-performance analytics securely in the cloud or on-premise; deliver frictionless analytics with self-indexing that automatically tunes performance; and scale out analytics for one transparent price. To learn more, please visit: www.exasol.com

###

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye